Quantcast

Latest Vaccination Stories

2014-06-23 23:10:50

Andrea Seratte, Executive Vice President of TransactRx will be presenting at the annual NACCHO conference held in Atlanta, GA July 8th – 10th. Mrs. Seratte will be presenting on the topic: Building Public Health Capacity Through the Provision Vaccination Programs Through the Use of Innovative Technology, along with Neal Lustig, BS, MPH, Director of Health of the Pomperaug District Department of Health (PDDH). Coral Gables, FL (PRWEB) June 23, 2014 Andrea Seratte, Executive Vice...

2014-06-23 12:29:48

PARIS, June 23, 2014 /PRNewswire/ -- OSE Pharma SA receives a positive agreement to initiate a Phase 3 clinical trial with OSE-2101, a therapeutic cancer vaccine for non-small cell lung cancer (NSCLC) OSE Pharma SA, a European cancer immunotherapy company with a specific T cytotoxic technology, today announced that it has received positive feedback from an end of Phase 2 / Pre-Phase 3 meeting with the U.S. Food and Drug Administration (FDA) and Scientific Advice from...

2014-06-23 04:20:45

Inovio's Immunotherapy will Treat Women with Inoperable HPV-caused Cancer BLUE BELL, Pa., June 23, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) today announced it has initiated a phase I/IIa clinical trial to evaluate safety, immunogenicity, clinical responses and disease-free survival of its DNA immunotherapy product, INO-3112, in treating human papillomavirus (HPV)-associated cervical cancer. INO-3112 is a combination of Inovio's lead active immunotherapy...

2014-06-18 16:26:28

Breaking New Ground in a Collective Search for Vaccines against Major Killer Diseases NEW YORK, June 18, 2014 /PRNewswire-USNewswire/ -- New technologies and insights in antigen discovery, genomics and immunological monitoring offer tremendous potential that could be collectively leveraged to speed development of vaccines against major diseases, according to leading scientists who met across specializations to explore creation of a Human Vaccines Project and reported their...

2014-06-17 12:29:52

ZUG, Switzerland, June 17, 2014 /PRNewswire/ -- Swiss-based AmVac AG, a private biotech company focused on the development of innovative vaccines, announced today the initiation of a Phase III study with AmVac's lead vaccine Gynevac in Bacterial Vaginosis (BV). The trial aims to confirm the safety and efficacy of a new generation of the vaccine produced in accordance to the current GMP standards. The previous version, containing Thiomersal, had been approved in Hungary in 1997...

2014-06-17 12:28:42

MERIDEN, Conn., June 17, 2014 /PRNewswire/ -- Protein Sciences Corporation announced today that BARDA, within the U.S. Department of Health and Human Services, exercised Option Period 2 of its contract with the Company (contract number HHS0100200900106C) to support development, scale-up and expanded licensure of the Company's influenza vaccines, Flublok® (seasonal) and Panblok® (pandemic). Option Period 2 has a budget of $50.6 million and will run through December 31, 2015. The...

2014-06-17 12:28:21

WORCESTER, Mass. and TORONTO, June 17, 2014 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTCBB: GNBT) today announced the posting of an interview given by Dr. Eric von Hofe, Ph.D., President of the Company's wholly-owned subsidiary, Antigen Express, Inc. (www.antigenexpress.com), following his keynote presentation at the recent TIDES meeting. The 16(th) Annual TIDES Conference (www.IBCLifeSciences.com/Tides) was held in Providence, RI May 12 - 15, 2014. TIDES,...

2014-06-17 04:21:35

Expanded License Includes New Product Candidates for Cancer, Infectious Diseases and Novel Immune Activators BLUE BELL, Pa., June 17, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) has expanded its existing license agreement with the University of Pennsylvania, adding exclusive worldwide rights to technology and intellectual property for novel synthetic therapies against cancer, infectious diseases and new immune activators. Inovio has an ongoing collaborative research...

2014-06-16 16:25:10

AMES, Iowa, June 16, 2014 /PRNewswire/ -- Ames, Iowa-based vaccine producer, Harrisvaccines, today announced it has been granted United States Department of Agriculture (USDA) conditional licensure of the company's Porcine Epidemic Diarrhea Virus (PEDv) Vaccine, RNA utilizing its SirraVax(SM )RNA Particle Technology. This is the first USDA conditional license granted for a PEDv vaccine since the initial outbreak, and it will allow Harrisvaccines to sell their vaccine directly to the...

California Public Health Dept Responds To Whooping Cough Outbreak
2014-06-16 13:36:55

Brett Smith for redOrbit.com - Your Universe Online On Friday, California’s Department of Public Health announced that the state is currently experiencing an epidemic of whooping cough and called for pregnant Californians to get vaccinated against the disease. “Preventing severe disease and death in infants is our highest priority,” said Dr. Ron Chapman, director of the California Department of Public Health (CDPH) and state health officer. “We urge all pregnant women to get...


Latest Vaccination Reference Libraries

0_ac8af9115d7f37daaaa2af4dba273fb1
2011-01-11 14:17:29

The Cowpox virus causes a skin disease known as cowpox. It is related to the vaccinia virus and gained its name because it spread by dairymaids touching the udders of infected cows. It manifests as red blisters. It is similar to smallpox although much milder and was actually the basis of the first smallpox vaccine. A person who recovers from cowpox is immune to smallpox. In 1980 the World Health Organization announced that smallpox was the first disease to be eradicated world wide by a...

More Articles (1 articles) »
Word of the Day
kenspeckle
  • Having so marked an appearance as easily to be recognized.
This word may come from the Swedish 'kanspak,' quick at recognizing persons or things, or else from confusion with 'conspicuous.'